LITS Key Statistics, Chart & Performance
The current stock price of LITS is 1.06 USD. In the past month the price decreased by -31.17%.
LITS Technical Analysis
LITS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to LITS. While LITS has a great health rating, there are worries on its profitability.
LITS Financial Highlights
Over the last trailing twelve months LITS reported a non-GAAP Earnings per Share(EPS) of -2.39. The EPS decreased by -189.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -87.2% | ||
| ROE | -94.18% | ||
| Debt/Equity | 0 |
LITS Forecast & Estimates
LITS Ownership
LITS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.95 | 383.716B | ||
| AMGN | AMGEN INC | 16.25 | 197.191B | ||
| GILD | GILEAD SCIENCES INC | 16.37 | 181.425B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.11 | 119.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.68 | 81.459B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.14 | 46.497B | ||
| INSM | INSMED INC | N/A | 32.511B | ||
| NTRA | NATERA INC | N/A | 28.376B | ||
| BIIB | BIOGEN INC | 12.01 | 27.206B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.38 | 20.78B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About LITS
Company Profile
Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
Company Info
LITE STRATEGY INC
9920 Pacific Heights Blvd, Suite 150
San Diego CALIFORNIA US
Employees: 4
Phone: 18583697100
LITE STRATEGY INC / LITS FAQ
What does LITE STRATEGY INC do?
Lite Strategy, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical compounds. The company is headquartered in San Diego, California and currently employs 4 full-time employees. The company went IPO on 2003-12-18. The firm accumulates pure LTC through active treasury management and concentrates holdings per share as the ultimate metric of shareholder value. The company is a clinical-stage pharmaceutical company focused on the development of differentiated cancer therapies intended to improve outcomes for patients. Its approach to oncology drug development is to evaluate its drug candidates in combination with standard-of-care therapies to overcome known resistance mechanisms and address clear medical needs. The portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor, and zandelisib, an oral, once-daily, selective PI3Kd inhibitor. Voruciclib is a selective orally administered CDK9 inhibitor with potential to treat both hematological malignancies and solid tumors. Voruciclib, a selective orally administered inhibitor of CDK9, is in clinical development for acute myeloid leukemia.
Can you provide the latest stock price for LITE STRATEGY INC?
The current stock price of LITS is 1.06 USD. The price decreased by -7.83% in the last trading session.
Does LITE STRATEGY INC pay dividends?
LITS does not pay a dividend.
How is the ChartMill rating for LITE STRATEGY INC?
LITS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
When is the next dividend date for LITE STRATEGY INC (LITS)?
The next ex-dividend date for LITE STRATEGY INC (LITS) is November 16, 2023.
What is the next earnings date for LITS stock?
LITE STRATEGY INC (LITS) will report earnings on 2026-02-10.